trial · primary record
Bevacizumab
GBM
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 6 |
| Primary completion | 2028-12-01 |
| Primary endpoint | Regimen-Limiting Toxicity |
| Registry ID | NCT07909811 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:53.314Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07909811
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Bevacizumab · compound